Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz

AIDS. 2000 Mar 31;14(5):626-8. doi: 10.1097/00002030-200003310-00025.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkynes
  • Anti-HIV Agents / therapeutic use*
  • Benzoxazines
  • Clinical Trials as Topic
  • Cyclopropanes
  • Drug Resistance, Microbial / genetics*
  • Drug Therapy, Combination
  • HIV / drug effects*
  • HIV / genetics
  • HIV Infections / drug therapy
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Oxazines / therapeutic use
  • Phenotype
  • Ritonavir / therapeutic use
  • Saquinavir / therapeutic use
  • Treatment Failure

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • HIV Protease Inhibitors
  • Oxazines
  • efavirenz
  • Saquinavir
  • Ritonavir